We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Enzon Opens a Phase 2 Study of PEG-SN38 for Metastatic Breast Cancer
News

Enzon Opens a Phase 2 Study of PEG-SN38 for Metastatic Breast Cancer

Enzon Opens a Phase 2 Study of PEG-SN38 for Metastatic Breast Cancer
News

Enzon Opens a Phase 2 Study of PEG-SN38 for Metastatic Breast Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Enzon Opens a Phase 2 Study of PEG-SN38 for Metastatic Breast Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Enzon Pharmaceuticals, Inc. announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer.

PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection).

The study is designed to evaluate the efficacy of single-agent PEG-SN38 in two groups of patients who have received prior therapy regimens of anthracycline and taxane or anthracycline, taxane and Xeloda. The PEG-SN38 compound is currently being evaluated in a Phase 2 study for metastatic colorectal cancer.

“We continue to be encouraged by our PEG-SN38 compound and are pleased to be advancing it into additional areas of cancer”

"We continue to be encouraged by our PEG-SN38 compound and are pleased to be advancing it into additional areas of cancer,” said Jeffrey H. Buchalter, Enzon's president and chief executive officer. "We look forward to providing updates on PEG-SN38 and the rest of our novel pipeline as data becomes available.”

“Irinotecan is known to be active in metastatic breast cancer but toxicity has limited its broad use. We are very excited about evaluating the novel PEG-SN38 compound in hopes that it will exhibit an improved treatment for metastatic breast cancer patients,” said Dr Joyce O'Shaughnessy, Baylor-Charles A. Sammons Cancer Center.
Advertisement